In addition, the systemic delivery of NO significantly downregulated HIF-1α levels, reversed hypoxia-induced DOX resistance, and enhanced anti-tumor immune responses by reprogramming the tumor immune microenvironment. This evidence concerns the gene HIF1A and neoplasm.